SAN DIEGO, March 7, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present
preclinical data from studies involving in vivo intratumoral IL-12 treatment in mouse cancer models. The data will be
presented in a poster at an upcoming Keystone Symposia conference. In addition, Punit Dhillon,
OncoSec President and CEO, will present a corporate overview at two investment conferences this month, including: Maxim
Group's Inaugural Healthcare Investor & Partnering Conference and the 2017 BIO Asia International Conference.
Keystone Symposia Conference: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology
OncoSec will present a poster at the Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology conference to be
held on March 19-23, 2017, in Whistler, British Columbia, Canada.
Details of the presentation are as follows:
|
Abstract Title: Intratumoral electroporation-mediated IL-12 gene
therapy can enhance tumor Immunogenicity (Poster #2074)
|
|
|
|
|
Date and Time: Tuesday, March 21, 2017 at 11:00 AM PST
|
|
|
|
|
Location: Fairmont Chateau Whistler
|
|
Further details on this Keystone Symposia poster presentation will be provided in upcoming Company communications. For more
information about this conference, please visit: http://keystonesymposia.org .
Maxim Group's Inaugural Healthcare Investor & Partnering Conference
Mr. Dhillon will present a corporate overview at Maxim Group's Biotech Investor & Partnering
Conference on March 7, 2017 at 11:20 AM China Standard Time at The
Park Hyatt Shanghai in Shanghai, China. In addition, he will participate in a panel discussion
entitled: "Innovations in Oncology – From Chemo to Immunotherapy" on the same day at 10:00
AM local time. For more information about this conference, please visit: http://www.maximgrp.com .
BIO Asia International Conference
Mr. Dhillon will present a corporate overview at the BIO Asia International Conference on March 14,
2017 at 11:15 AM Japanese Standard Time at the Grand Hyatt Tokyo in Tokyo, Japan. For more information about this conference, please visit: https://www.bio.org/events/bio
- asia - international conference .
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of
DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a
systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for
metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in
patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse®
IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For
more information, please visit www.oncosec.com.
CONTACTS:
Investor Relations:
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media:
Laura Radocaj
DGI Comm
212-825-3210
media@oncosec.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-in-march-300419332.html
SOURCE OncoSec Medical Incorporated